HC Wainwright Reaffirms “Buy” Rating for Agenus (NASDAQ:AGEN)

HC Wainwright reaffirmed their buy rating on shares of Agenus (NASDAQ:AGEN) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $40.00 target price on the biotechnology company’s stock.

Several other research analysts have also issued reports on AGEN. B. Riley dropped their target price on Agenus from $120.00 to $100.00 and set a buy rating for the company in a research report on Monday, March 18th. StockNews.com initiated coverage on Agenus in a report on Wednesday, April 17th. They issued a hold rating for the company.

Agenus Trading Down 0.4 %

Shares of AGEN stock opened at $16.69 on Friday. Agenus has a 12-month low of $4.78 and a 12-month high of $38.60. The stock’s 50-day moving average price is $13.45 and its 200-day moving average price is $12.94. The stock has a market capitalization of $350.49 million, a price-to-earnings ratio of -1.30 and a beta of 1.32.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($3.04) earnings per share for the quarter, topping the consensus estimate of ($3.58) by $0.54. The company had revenue of $28.01 million for the quarter, compared to the consensus estimate of $40.70 million. As a group, research analysts predict that Agenus will post -9.7 EPS for the current fiscal year.

Institutional Trading of Agenus

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Agenus by 13.7% during the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after buying an additional 4,134,232 shares during the period. Braidwell LP lifted its holdings in Agenus by 34.3% during the third quarter. Braidwell LP now owns 6,307,030 shares of the biotechnology company’s stock worth $7,127,000 after buying an additional 1,609,100 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Agenus by 3,008.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock worth $1,909,000 after buying an additional 2,232,064 shares during the period. Readystate Asset Management LP lifted its holdings in Agenus by 14.3% during the fourth quarter. Readystate Asset Management LP now owns 2,016,783 shares of the biotechnology company’s stock worth $1,670,000 after buying an additional 252,124 shares during the period. Finally, Cardinal Strategic Wealth Guidance lifted its holdings in Agenus by 28.2% during the fourth quarter. Cardinal Strategic Wealth Guidance now owns 910,265 shares of the biotechnology company’s stock worth $754,000 after buying an additional 200,000 shares during the period. Hedge funds and other institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.